The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - Affimed (AFMD) has been on a tear lately as markets are starting to realize the potential of the company’s pipeline. It is trading above $4/share … Continue Reading
PremiumInsights - We had a call with Essa (EPIX) management earlier today. The initial thesis was that Essa’s second-generation drug would address the issues and potency limitations … Continue Reading
PremiumInsights - Essa Pharma (EPIX) is entering a second-gen drug, with a novel mechanism of action, into clinic for advanced prostate cancer The first-gen drug showed to … Continue Reading
PremiumInsights - Last Friday, San Raffaele Hospital in Milan, Italy, published data using La Jolla’s Giapreza in compassionate use. The study demonstrated that Giapreza was able to improve oxygenation … Continue Reading
PremiumInsights - Affimed & Genentech/Roche released their preclinical abstract for an anti-BCMA/CD16a bi-specific antibody in multiple myeloma today for the American Association of Cancer Research (AACR) conference. This affiliation confirms the … Continue Reading
PremiumInsights - Aimmune announced their first quarter of Palforzia launch yesterday and it was greatly impacted by Covid. Sales for the quarter were $600K, about half of the Street’s projection … Continue Reading
PremiumInsights - La Jolla (LJPC) released Q1 numbers today. Although we were expecting a larger jump, as a result of the COVID situation and increase in demand … Continue Reading
Premium
